Trial Profile

An initial U.S. clinical trial of SYN-2510/IMM2510 as a monotherapy or in combination with chemotherapy as a first-line in patients with non-small cell lung cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Jan 2026 According to an Instil Bio media release, company has decided to discontinue clinical development of AXN-2510, and that Axion and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. have entered into an agreement to terminate their license and collaboration arrangement for AXN-2510 and AXN-27M.
04 Mar 2025 According to Instil Bio media release, the company anticipates initiating a U.S. clinical trial of AXN-2510/IMM2510 in combination with chemotherapy for 1L NSCLC patients before the end of 2025, assuming the necessary regulatory approvals are obtained.
04 Mar 2025 According to Instil Bio media release, the company Planned 100 patients in this trial

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com